Search company, investor...
Chrono Therapeutics company logo

Chrono Therapeutics


Series B | Dead

Total Raised


Last Raised


About Chrono Therapeutics

Chrono Therapeutics (CHRONO) was founded in 2004 with a vision of transforming disease and addiction management in wearable, patient optimized drug delivery. With real-time wireless connectivity and tailored behavioral support, Chrono's science of specifically tailoring the timing and dose sizes of drugs, preempts predictable peak disease and addiction symptoms with an easy-to-use device. In partnership with the University of Basel, Switzerland and three affiliate Universities, CHRONO has built a pipeline of pharmaceutical applications. The fruition of these efforts will see a wide-spread impact to better manage common conditions and diseases with next generation "Smart" drug products.

Headquarters Location

3953 Point Eden Way

Hayward, California, 94545,

United States


Missing: Chrono Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Chrono Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Chrono Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Chrono Therapeutics is included in 5 Expert Collections, including Wearable Computing.


Wearable Computing

428 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.


Medical Devices

8,633 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Smart Home & Consumer Electronics

1,234 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.


Digital Health

10,341 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Health IT

7,901 items

Chrono Therapeutics Patents

Chrono Therapeutics has filed 26 patents.

The 3 most popular patent topics include:

  • Abandoned drugs
  • Amines
  • Calcium channel blockers
patents chart

Application Date

Grant Date


Related Topics




Amines, Piperidines, Fluoroarenes, Abandoned drugs, Calcium channel blockers


Application Date


Grant Date



Related Topics

Amines, Piperidines, Fluoroarenes, Abandoned drugs, Calcium channel blockers



Latest Chrono Therapeutics News

Scientific Rationale And Innovations On A.M. Surge Management Through Chrono Therapeutics

Jan 4, 2023

World Health Organization - An estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries. The number of adults with hypertension increased from 594 million in 1975 to 1.13 billion in 2015, with the increase seen largely in low- and middle-income countries. Hypertension is a major cause of premature death worldwide. One of the global targets for non-communicable diseases is to reduce the prevalence of hypertension by 33% between 2010 and 2030. Reference: Early Morning BP surge, an increase in Blood Pressure over the transition from being asleep to awake exaggerates. During the early morning hours not only rapid rise in blood pressure but also cardiovascular events predominate. Thus, it appears that the early morning hours are the hours of highest cardiovascular risk and is the need of hour to deliver optimum amount of drug. Diltiazem Hydrochloride (A Calcium channel blocker) produces antihypertensive effect by relaxation of vascular smooth muscle and Propranolol Hydrochloride (A Beta blocker) contributes to antihypertensive effect due to decreased cardiac output, diminution of tonic sympathetic nerve outflow and inhibition of renin release by the kidneys, however upon oral administration of an immediate release formulation both drugs undergoes a substantial Hepatic first pass effect and absolute bioavailability is only 40%, and 25% respectively. Hence the selected drug candidates in due consideration of disease pattern were encapsulated in a hardened gelatin shell and targeted to deliver in the colonic region, a potential site for the systemic absorption. Dr. Vamsi Krishan Birupaneni, as part of his PhD thesis designed a Pulsatile release systems to undergo a lag-time of predetermined span of no release, followed by a rapid and complete release of loaded drugs. The approach is based on the principle of delaying the time of drug release until the system transits from mouth to colon. A lag-time of 5 hours is usually considered sufficient since transit time to reach colon is about 5 hours, which is relatively constant and hardly affected by the nature of formulation administered. Dr. Vamsi Krishan has established rationale for the selection of polymers that are highly compatible with colon, such as Eudragit NM 30 D, Eudragit RL 30 D, and Eudragit FS 30 D by performing all the pre-formulation studies. As part of formulation of drug pellets by wurster technique and encapsulating in the hardened gelatin capsule, he optimized various process parameters of fluidized bed processors such as Inlet and outlet air temperatures, Atomization air pressure, and Blower speed and spray rate and as a whole have good propensity of scaling up the formulation to satisfy the futuristic purpose. A systematic evaluation of the designed pulsatile drug delivery system was carried out by Dr. Vamsi Krishan and his team with due consideration of Physico chemical properties of the components, establishment of invitro release profile of pulsatile capsule, stability of the dosage form in line with ICH guidelines and determined Pharmacokinetic and pharmacodynamics parameters on healthy rabbits. In agreement with pharmacokinetic data and pharmacodynamics evaluations on rabbits, with pulsatile formulations of Propranolol hydrochloride formulations, maximum ß -blockade was obtained at 12.0 hrs. and was prolonged over a period of 18 hrs. For Diltiazem hydrochloride formulations, a maximum protection against adrenaline challenge was obtained at 12 hrs. And was prolonged over a period of 18 hrs. Against a 6 hrs. Maximum protection with an oral sustained formulations. The dosage form can be administered at bedtime and will release the contents in the early morning hours when the risk of hypertension thus synchronizing release profile with chronobiologic antihypertensive therapy and deliver the drug at specific time as per pathophysiological needs of the disease, improve therapeutic efficacy. It embodies time controlled and site-specific drug delivery systems, subsequently optimizing therapeutic action and lessening side effects. The research work was published in UGC approved journals, being cited and was an instrumental in few more research works carried out by other researchers. In addition exhibited at several national and international platforms like ICMBPS-22, Reignite international conference, UCG-Dubai and highly appreciated due to the scope of usage of current delivery system to other therapies like Cancer, Arthritis and Asthma and meet the unmet needs of patients at affordable cost. Dr. Vamsi Krishan was awarded as the 2nd best speaker for his profound skills on the Chrono-pharmaceutical drug delivery system at 3rd International conference held by Reignite conferences and his research work was acknowledged by Association of Pharmaceutical Teachers of India (APTI) in their Bulletin. Dr. Vamsi Krishan have been engaged in various inter disciplinary functions and handled various projects related to complex injectable, ophthalmic and Liposomes, awarded Quarterly technical awards at Organizational level. Source: World Health Organization

Chrono Therapeutics Frequently Asked Questions (FAQ)

  • Where is Chrono Therapeutics's headquarters?

    Chrono Therapeutics's headquarters is located at 3953 Point Eden Way, Hayward.

  • What is Chrono Therapeutics's latest funding round?

    Chrono Therapeutics's latest funding round is Series B.

  • How much did Chrono Therapeutics raise?

    Chrono Therapeutics raised a total of $84.73M.

  • Who are the investors of Chrono Therapeutics?

    Investors of Chrono Therapeutics include 5AM Ventures, Mayo Clinic Ventures, GE Ventures, Fountain Healthcare Partners, Canaan Partners and 12 more.

  • Who are Chrono Therapeutics's competitors?

    Competitors of Chrono Therapeutics include Proteus Digital Health and 1 more.

Compare Chrono Therapeutics to Competitors

AdhereTech Logo

Digital Medical Technologies, dba AdhereTech, creates bottles that measure pills or liquid in real-time, wirelessly send this HIPAA-compliant data into the cloud, and remind patients to take their medication via automated phone call or text message.

MediSafe Logo

MediSafe develops a medication engagement platform. The platform helps people integrate healthier behavior into their daily lives with a cloud-synced mobile medication management system. It offers solutions, data insights, research, webinars, case studies, and more. The company is founded in 2012 and is based in Needham, Massachusetts.


AiCure operates as an artificial intelligence (AI) and advanced data analytics company targeting the healthcare industry. It uses artificial intelligence (AI) to understand people's responses regarding clinical trials and patient care. The company was founded in 2010 and is based in New York, New York.

Scene Health Logo
Scene Health

Scene develops a mobile health platform for remote healthcare management. It uses video technology and human engagement to help patients take doses of medication as prescribed. The company operates through dose-by-dose observation and clinical assessment of potential administration problems such as technique and side effects. It was formerly known as emocha Health. The company was founded in 2018 and is based in Brooklandville, Maryland.

Pill Connect Logo
Pill Connect

Pill Connect is a med-tech company that develops a patented smart dosing system for medicine adherence monitoring. The company's devices support patients to take their medicine properly and provide real-time remote monitoring to healthcare professionals. Pill Connect was founded in 2013 and is based in Manchester, England.

Fellow Logo

Fellow helps chronically ill patients manage complex medication regimens. Patients using Fellow's service receive pre-filled medication trays that insert into a connected pillbox, facilitating complex regimens with preformed ease akin to a single-serve coffee machine. The connected pillbox senses when patients forget medication doses and send an automated text message or phone reminders to patients and their loved ones. Fellow combines pharmacy packaging, hardware, software, and automated reminders to make the entire medication process easier for high-risk patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.